Untargeted Metabolomics and Metabolite–Gene Network Analysis Predict NF-κB Inhibition in Artemisian B-Treated Triple-Negative Breast Cancer Cells
Open Access
- 28 May 2026
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 16 (6) , 365
Abstract
Background: Triple-negative breast cancer (TNBC) remains a formidable clinical challenge due to the scarcity of targeted therapies and profound metabolic heterogeneity. Although Artemisian B, a dimeric sesquiterpene lactone derived from Artemisia argyi, exhibits potent antiproliferative activity, its comprehensive metabolic footprint and the translation of these perturbations into downstream signaling regulation remain poorly characterized. Methods: To address this gap, we employed an integrative analytical framework combining untargeted metabolomics, topology-guided metabolite–gene network mapping, and parallel experimental validation in MDA-MB-231 cells. This workflow systematically profiled cellular phenotypes, global metabolic reprogramming, and key signaling nodes, enabling the prioritization of high-confidence mechanistic links between metabolic alterations and signal transduction. Results: Artemisian B dose-dependently suppressed TNBC cell viability (IC50 = 12.12 μM) and triggered mitochondrial apoptosis, characterized by Bax upregulation, Bcl-2 downregulation, and caspase-9/3 activation. Untargeted metabolomics identified 129 significantly altered metabolites, reflecting extensive dysregulation across lipid peroxidation, bioenergetics, and nucleotide metabolism. Topological analysis of the metabolite–gene network identified the NF-κB pathway as a highly interconnected hub within this perturbed landscape. Parallel experimental validation corroborated this prediction, demonstrating that Artemisian B consistently suppressed the phosphorylation of IKKα/β, IκBα, and p65, while markedly attenuating p65 nuclear translocation. Conclusions: Artemisian B induces TNBC apoptosis through extensive metabolic reprogramming coupled with concurrent inhibition of NF-κB signaling. By seamlessly integrating untargeted metabolomics with network topology, our framework not only successfully bridges metabolic perturbations with signaling outcomes but also establishes a versatile, dual-perspective strategy applicable to both biochemical reaction networks and signal transduction pathways. This approach provides a robust predictive paradigm for decoding the multi-target pharmacological mechanisms of natural products.Keywords
Funding Information
- National Natural Science Foundation of China (81773857)
This publication has 36 references indexed in Scilit:
- Systems lipidomics reveals sesamin-driven suppression of lipid metabolic reprogramming via AMPK activation in triple-negative breast cancer cellsBiochemical and Biophysical Research Communications, 2025
- Metabolite classification through novel metabolomics framework reveals mechanism underlying the therapeutic effects of PSD95-nNOS blockade for post-stroke depressionMetabolomics, 2025
- Sonopermeation combined with stroma normalization enables complete cure using nano-immunotherapy in murine breast tumorsJournal of Controlled Release, 2025
- AMPK: The energy sensor at the crossroads of aging and cancerSeminars in Cancer Biology, 2024
- Cancer Epigenetics: An OverviewArchives of Medical Research, 2022
- The hallmarks of cancer metabolism: Still emergingCell Metabolism, 2022
- Metabolic reprogramming and epigenetic modifications on the path to cancerProtein & Cell, 2021
- The Warburg Effect: How Does it Benefit Cancer Cells?Trends in Biochemical Sciences, 2016
- Proposed minimum reporting standards for chemical analysisMetabolomics, 2007
- Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease CascadeCell, 1997